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Abstract
Background: One-quarter of neonatal and infant deaths are due to infection, and the majority of these deaths occur
in developing countries. Standard treatment for infection, which includes parenteral treatment only, is often not
available in low-resource settings. Infant mortality will not be reduced in developing countries without a reduction in
deaths due to infection. We participated in a multi-site trial that demonstrated the effectiveness of three simplified
antibiotic regimens compared to standard treatment (The AFRINEST Trial: parent study). For this report, we examined
the site-specific data for the Democratic Republic Congo (DRC), the most impoverished of the countries that
participated in the study, to determine if outcomes in the DRC were similar to outcomes across all sites.
Methods: The parent study was an individually randomized, open-label, equivalence trial. Infants with clinical signs of
severe infection were randomized to receive one of four regimens: 1) injectable penicillin-gentamicin for 7 days
(standard therapy; regimen A), 2) injectable gentamicin and oral amoxicillin for 7 days (regimen B), 3) injectable
penicillin-gentamicin for 2 days then oral amoxicillin for 5 days (regimen C), or 4) injectable gentamicin for 2 days and
oral amoxicillin for 5 days (regimen D). In the DRC, we enrolled 574 infants, of whom 560 met the per-protocol criteria
for analysis of treatment effect. The main outcome was treatment failure within the first week of enrollment.
Results: Treatment failure occurred in 52 (9.3%) infants: 17 (11.6%) with the referent treatment regimen, 13 (9.6%) with
regimen B (risk difference [RD] -2.0%; CI -9.2% to 5.2%), 13 (9.0%) with regimen C (RD -2.6%; CI -9.6% to 4.4%), and 9 (6.
7%) with regimen D (RD -5.0%; CI -11.7% to 1.7%).
Conclusion: As in the parent study, the risk difference between each of the experimental treatments and the reference
treatment suggests equivalence. These findings suggest that the conclusion from the parent study, that a simplified
antibiotic regimen can be used for the community-based management of possible severe infection in young infants
where referral to a hospital for standard care is often not possible, is true in the DRC. We speculate that the widespread
use of a simplified, community-based treatment could result in increased coverage with treatment and improved
survival in poor areas.
Trial registration: ACTRN12610000286044 on April 9, 2010.
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Background
Reducing child mortality continues to be one of the most
vexing challenges in this Sustainable Development Goals
era. An estimated 5.6 million children died in 2016; ap-
proximately 2.6 million of these deaths occurred in the
neonatal period [1]. Of these child deaths, the proportion
occurring in neonates and young infants (infants 0–
2 months) continues to rise [2]. Evidence-based research,
policies, programs and advocacy that target this age group
are urgently needed to combat this problem.
Infections are among the leading causes of neonatal
and young infant mortality [1]. In 2012, over 0.66 mil-
lion infants died of serious bacterial infections, such as
pneumonia, sepsis, and meningitis [3]. Until 2015, the
World Health Organization (WHO) recommended that
all neonates and young infants with possible serious bac-
terial infections (PSBI) be treated in hospitals with in-
jectable antibiotic therapy for 7–10 days [4]. However,
this recommendation is difficult to implement in many
low-income countries, particularly in rural areas. The
Democratic Republic of Congo (DRC), located in central
Africa and the fourth most populous African country, is
particularly vulnerable to the challenges of implementing
these WHO recommendations. In the DRC, nearly all
health care in rural areas is provided through health cen-
ters that do not typically provide inpatient care. Pro-
viders in health centers may refer some patients to their
area hospital if inpatient care is advisable and feasible;
however, distances from health centers to hospitals vary
widely, ranging from less than one mile to 60 miles, the
terrain is challenging and obtaining transport poses im-
mense difficulties. For the patient who makes it to a refer-
ral hospital, the hospitals are lacking in sufficiently trained
health care providers, and equipment and essential medi-
cines are often absent [5]. As a result of these barriers,
many infants with PSBI are not taken to hospitals, and if
they do get there are either untreated or inadequately
treated. These barriers and inadequacies of treatment con-
tribute to the neonatal mortality in these regions.
Because of these barriers to recommended treatment
in the DRC and other resource-limited countries, a col-
laboration of investigators from the WHO and the Uni-
versities of Kinshasa and North Carolina participated in
a multi-site study (five sites from three countries) that
examined the efficacy of four simplified regimens of out-
patient antibiotic therapy for the treatment of neonates
and young infants with PBSI [6]. The results of the
multi-center study (the African Neonatal Sepsis Trial:
AFRINEST Trial) were published in the Lancet and sug-
gest that these infections could be treated effectively out-
side of referral hospitals, in health centers or homes [7].
The WHO modified its recommendations for treatment
of PSBI based, in part, on the results of this study [8].
However, each of the five sites had unique demography,
geography and healthcare infrastructure that might pre-
dict variation in efficacy among sites. The objective of
this report is to examine the DRC site-specific data from
the multi-site study to determine the comparative effi-
cacy of these treatment regimens in the cohort enrolled
in the DRC, the most rural and impoverished of the
study sites.
Methods
Study site
Our site was in rural areas of the North and South
Ubangi districts in the province of Equateur in northern
DRC. The overall population of the study area was
roughly 400,000. We included 30 health areas, each
served by a health center. Health centers are the primary
level facilities staffed by one trained nurse who provides
treatment to ill infants.
Study design:
The parent study was a multi-site, individually random-
ized, open-label, equivalence trial [6].
A. Eligibility Criteria
Young infants and neonates (0–59 days old) with signs
of PSBI and whose families did not accept or could not
access inpatient hospital care for whatever reason were
enrolled and randomized. Signs of PSBI included: not
feeding well, movement only when stimulated, severe
chest indrawing and axillary temperature > 38.0 °C or <
35.5 °C. We excluded infants who had very low weight
(< 1500 g) at the time of presentation, had been hospital-
ized for illness in the previous two weeks or prior to in-
clusion in the study, any sign of critical illness
(unconscious, convulsions, unable to feed at all, apnea,
unable to cry, cyanosis, dehydration, bulging fontanel),
major congenital malformations inhibiting oral antibiotic
intake, active bleeding requiring transfusion, surgical
conditions needing hospital referral, and persistent
vomiting (vomiting following three attempts to feed the
baby within one-half hour).
B. Surveillance
We developed an active surveillance system in order
to maintain a registry of infants in the study communi-
ties. At the beginning of the trial, we used community
health workers (CHWs) to conduct a household census
in order to identify all births and pregnant women.
CHWs repeated the household census every three to
four months. We incorporated other methods to dis-
cover pregnancies and births: self-reporting of pregnan-
cies to a CHW, identification of pregnant women at
antenatal clinics in the community health facilities, and
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referrals from traditional birth attendants (TBAs) or
other key informants.
C. Enrollment
CHWs visited the homes of newborns on postnatal
days 1, 3, 7, 14, 21, 28, 35, 42, 49 and 60. During these
home visits, the CHWs provided standardized advice to
the family regarding newborn care, as described in the
WHO/UNICEF Joint Statement on home-based care of
newborns [6]. At each home visit, CHWs assessed the
newborn for signs of illness and counseled the families
on recognition of danger signs of infection. Young in-
fants who exhibited danger signs were referred to a
health center for evaluation.
All infants who presented with danger signs were
evaluated by a study nurse. This assessment was in
addition to and independent of an assessment per-
formed by a health center provider, and occurred ei-
ther in the health center or in the home. If the study
nurse confirmed that a danger sign and PSBI was
present, the infant was referred to local hospital facil-
ity, as recommended in the WHO Integrated Manage-
ment of Children Illness (IMCI) guidelines [9]. If the
family refused to accept hospital referral despite the
best efforts of the study nurse, they were considered
for enrollment in the study.
D. Consent
Consent for study participation was obtained by the
study nurse at the health facility or at home in the pres-
ence of a witness. Consent included detailed oral com-
munication about the trial and study procedure in the
study participant’s native language. Illiterate parents
were asked to provide a thumbprint on the consent
form; literate parents were requested to sign the con-
sent form.
E. Randomization and Allocation Concealment
Prior to randomization, infants with PSBI were
stratified by age at presentation (< 7 days old and 7
to 59 days old) and assigned to one of four treatment
regimens. For allocation concealment, the treatment
code for each study infant was sealed in an envelope,
one color for each age stratum. Each cluster (a group
of health centers) was given envelopes for a set of
blocks. When the first infant was enrolled in a cluster
in a stratum, the first envelope of the first block for
that age stratum was opened, and the infant was
treated according to the treatment code inside. When
the next infant was enrolled, the next envelope of the
block was opened.
F. Treatment Regimens
Each patient was randomized to one of four treatment
regimens:
 Treatment regimen A (reference treatment):
gentamicin (desired range 4–5 mg/kg/day) by
intramuscular (IM) injection once daily, and
procaine penicillin (desired range 40,000–
50,000 units/kg/day) by IM injection once daily for
7 days (14 injections in total)
 Treatment regimen B: gentamicin (desired range 4–
5 mg/kg/day) by IM injection once daily and oral
amoxicillin (desired range 75–100 mg/kg/day) twice
daily for 7 days (7 injections in total)
 Treatment regimen C: gentamicin (desired range 4–
5 mg/kg/day) by IM injection once daily and
procaine penicillin (desired range 40,000–
50,000 units/kg/day by IM injection once daily for
2 days; thereafter oral amoxicillin (desired range 75–
100 mg/kg/day) for 5 days (4 injections in total)
 Treatment regimen D: gentamicin (desired range 4–
5 mg/kg/day) by IM injection once daily for two
days and oral amoxicillin (desired range 75–100 mg/
kg/day) twice daily for 7 days; (2 injections in total)
Study outcomes
Treatment failure within day 1–8 following enrollment
was the primary outcome and was defined as any one of
the following: death, clinical deterioration (hospitalization,
emergence of any sign of critical illness, a new sign of se-
vere infection, or re-emergence of a sign of severe infec-
tion on day 4 after it had initially disappeared), no
improvement in clinical condition by day 4 (if single sign
of severe infection was present at enrollment, persistence
of the sign, and if multiple signs were present at enroll-
ment, persistence of > 1 sign), no clinical cure by day 8
(persistence of any sign of severe infection on day 8), de-
velopment of a serious adverse effect to the study antibi-
otics, or withdrawal of informed consent, any time
between days 1–8.
Sample size and analysis plan
The sample size for the parent study was based on an
estimated incidence of severe bacterial infection among
neonates and young infants of 5%. The analytic plan was
to compare failure rates of treatment regimens B, C and
D to failure rates following treatment regimen A. Com-
parisons were made for similarity of effectiveness de-
fined by the upper limit of the 95% confidence interval
of the differences in failure rate lying below the similar-
ity margin of + 5%. In the parent study, the required
sample for 90% power to demonstrate the similarity of
any two treatments assuming that the true failure rates
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with the reference treatment and the experimental treat-
ment regimens were identical (assumed to be 10%) was
estimated to be a total 3040. An additional 560 infants
were added to the planned enrollment to allow for fail-
ures of adherence to the protocol to allow for both per-
protocol and intention-to-treat analyses. Sample size cal-
culations for individual sites were not calculated because
there was no a priori intent to perform sit-specific ana-
lyses. Therefore, the sample size for the DRC was the
number enrolled at this site during the duration of the
parent study.
We conducted these single site analyses using STATA
version 12.0 (StataCorp, College Station, TX). We ana-
lyzed the primary outcome (treatment failure) per-
protocol, which is considered a more conservative analysis
than intention to treat (ITT) analysis for equivalence stud-
ies. We evaluated the difference in the risk of treatment
failure between the reference treatment (regimen A) and
all other treatments together with a 95% confidence inter-
val. We report planned investigation of secondary out-
comes and comparisons between features of the DRC and
the parent study cohort using descriptive statistics only.
Results
From September 17, 2012 to June 28, 2013, we enrolled
574 infants (Fig. 1), 16% of the 3564 infants enrolled in
the parent study. Mean maternal age at enrollment was
25 years, and 47% had no formal education. Nearly all
(95.3%) attended at least one antenatal clinic visit.
Among all infants, 398 (69%) were born in health
Fig. 1 CONSORT Diagram of Democratic Republic of Congo study cohort. Origin of the study cohort in the Democratic Republic of Congo. The
diagram illustrates the origin of the 560 infants whose outcomes were analyzed for treatment effect. Boxes to the right indicate when and why
infants were excluded
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centers, 66 (12%) in hospitals, and 85 (15%) at home.
Compared to all participants in the parent study, partici-
pants from the DRC had lower maternal education and
more used solid fuel for cooking (Table 1).
In the DRC, the randomization process allocated 148
(25.2%) infants to treatment regimen A, 139 (24.2%) to
regimen B, 148 (25.2%) to regimen C, and 139 (24.2%)
to regimen D. Enrollment occurred soon after birth for
many infants; 198 (34%) were enrolled in their first week
of life. Mothers and infants in each group had similar
baseline characteristics (Table 2). At enrollment, the
most common presenting signs was fever (57.0%). We
enrolled 75 infants (13.1%) with two or more signs.
Almost all infants, 98% received all treatment doses as
per-protocol analysis, and 97% received all independent
outcome assessment visits (Table 3). We excluded 14 in-
fants from our analysis of treatment effect because they
did not receive all treatment doses and adequate follow-
up as required by the study protocol [6].
Treatment failure occurred in 52 (9.2%) infants
(Table 4). When compared to the reference treatment,
the risk difference with regimen B was − 2.0% (95% CI:
-9.2 to 5.2), with regimen C: − 2.6% (− 9.6 to 4.4), and
with regimen D -5.0% (− 11.7 to 1.7) (Table 3). Among
treatment failures, 11 infants died; 9 had the appearance
of a sign of critical illness; 5 had a new sign of serious
infection; and 21 had no improvement in clinical condi-
tion by day 4. Treatment failure occurred most com-
monly on day 4 following enrollment.
Discussion
The AFRINEST Trial, a multi-national study, investi-
gated the safety and effectiveness of simplified regimens
for the management of possible serious bacterial infec-
tion among infants in resource-poor community set-
tings. This study enrolled 3564 infants in five sites in
three countries (Kenya, DRC, and Nigeria) [7]. In the
parent study, four week-long treatment regimens were
compared. The outcomes of infants treated with three
regimens of antibiotics that included combinations of
parenteral (intramuscular) and oral antibiotics were
compared to outcomes in a reference group treated with
daily doses of parenteral antibiotics, the standard care.
Treatment failure occurred in 6.8% of infants, but the
risk differences between the experimental treatment reg-
imens and the reference treatment were within the pre-
specified 5% similarity margin. The conclusion from this
study was that treatment with these regimens was
equivalent to the standard care.
The purpose of the study reported in this manuscript
was to determine whether the results from this multi-
national study could be reasonably extrapolated to the
DRC. The DRC is a unique environment compared to
the other sites for several reasons. First, mothers had less
education compared to other sites. Second, the socio-
economic status is lower in the DRC. Despite the abun-
dant natural resources of the country, the population of
the DRC is among the poorest in the world [10, 11]. Ac-
cording to the 2013 Human Development Report, the
DRC ranks last (186th) with a poverty ratio of about
80% [12]. This compares to ranks of 153rd and 145th for
Nigeria and Kenya. Third, the DRC has high fertility
rates and bigger families. The total fertility rate in the
DRC is 6.6, [13] compared to 5.5 in Nigeria [14] and 3.9
in Kenya [15].
As a participant in the multi-national study, we exam-
ined the safety and efficacy of simplified antibiotic regi-
mens compared with the reference treatment for the
management of neonates and young infants with PSBI
among infants enrolled in the study. Our site-specific
data demonstrated similarity between each of the experi-
mental treatment regimens and the reference treatment.
Treatment failure varied among groups from 11.6% to
Table 1 Demographics for DRC Site compared to AFRINEST
study population
DRC Site AFRINEST Study
Population
N = 574 n = 3564
Maternal age (years)
Mean (SD) 25.0 (6.4) 25.9 (5.8)
< 20 years 122 (21%) 440 (12%)
≥ 20 years 385 (67%) 1969 (84%)
Not known 67 (12%) 110 (3%)
Maternal education (years)
No formal school attendance 271 (47%) 625 (18%)
< 12 292 (51%) 2025 (57%)
≥ 12 11 (2%) 896 (25%)
unknown 0 (0%) 10 (< 1%)
Cooking place and fuel (n)
Indoor with solid fuel 315 (55%) 1534 (43%)
Outdoor with solid fuel 259 (45%) 771 (22%)
No solid fuel 0 1279 (36%)
Had at least 1 antenatal care
visit (n)
Yes 555 (97%) 3371 (95%)
No 19 (3%) 184 (5%)
Not known 0 9 (< 1%)
Number of previous live births
1 145 (25%) 847 (24%)
2–3 231 (40%) 1377 (39%)
> 4 198 (35%) 1342 (38%)
Not known 0 8 (< 1%)
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Table 2 Baseline characteristics of enrolled infants
Regimena A B C D
Number of infants enrolled 148 139 148 139
Age at enrollment (days) Mean (SD) 17 (15) 17 (15) 17 (16) 20 (17)
< 7 days 54 (36.5%) 46 (33.1%) 55 (37.2%) 43 (30.9%)
≥ 7 days 94 (63.5%) 93 (66.9%) 93 (62.8%) 96 (69.1%)
Sex Male 75 (50.7%) 76 (54.7%) 70 (47.3%) 81 (58.3%)
Respiratory rate Mean (SD) 69 (19) 69 (19) 70 (20) 67 (19)
< 60 54 (36.5%) 47 (33.8%) 52 (35.1%) 57 (41.0%)
60–70 27 (18.2%) 21 (15.1%) 26 (17.6%) 16 (11.5%)
70–79 22 (14.9%) 33 (23.7%) 26 (17.6%) 32 (23.7%)
80–89 24 (16.2%) 20 (14.4%) 25 (16.9%) 19 (13.7%)
90–99 8 (5.4%) 9 (6.5%) 9 (6.1%) 8 (5.8%)
≥ 100 13 (8.8%) 9 (6.5%) 10 (6.8%) 7 (5.0%)
Temperature < 35.5 6 (4.1%) 8 (5.8%) 12 (8.1%) 12 (8.6%)
35.5–37.9 39 (26.4%) 47 (33.8%) 44 (29.7%) 33 (23.7%)
≥38.0–38.9 96 (64.9%) 70 (50.4%) 80 (54.1%) 76 (54.7%)
≥39.0 7 (4.7%) 14 (10.1%) 12 (8.1%) 18 (12.9%)
Poor feeding 23 (15.5%) 22 (15.8%) 26 (17.6%) 25 (18.0%)
Movement only on stimulation 3 (2.0%) 5 (3.6%) 3 (2.0%) 1 (0.7%)
Severe chest indrawing 33 (22.3%) 40 (28.8%) 32 (21.6%) 31 (22.3%)
Number of signs at enrollment 1 129 (87.2%) 120 (86.3%) 128 (86.5%) 120 (86.3%)
2 18 (12.2%) 18 (12.9%) 17 (11.5%) 16 (11.5%)
≥ 3 1 (0.7%) 1 (0.7%) 1 (0.7%) 3 (2.2%)
aRegimen A: IM Gentamicin and IM Penicillin × 7 days; Regimen B: IM Gentamicin and oral amoxicillin × 7 days; Regimen C: IM Gentamicin × 7 days and IM
Penicillin × 2 days then oral amoxicillin × 5 days; Regimen D: IM Gentamicin × 2 days and oral amoxicillin × 7 days
Table 3 Treatment adherence and follow-up of enrolled infants
Regimena A B C D
Number of infants enrolled 148 139 148 139
Treatment adherence
Received all treatment doses as per-protocol 146 (98.6%) 137 (98.6%) 144 (97.3%) 135 (97.1%)
Did not receive all doses, but met per-protocol analysis criteria 2 (1.4%) 1 (0.7%) 4 (2.7%) 4 (2.9%)
Did not meet per-protocol analysis criteria for treatment 0 1b (0.7%) 0 0
Follow up by independent outcome assessor
Received all independent outcome assessment visits 145 (98.0%) 133 (95.7%) 145 (98.0%) 133 (95.7%)
Did not receive all independent outcome assessment visits,
but met per-protocol analysis criteria
2 (1.4%) 3 (2.2%) 2 (1.4%) 4 (2.9%)
Did not meet per-protocol analysis criteria for assessment 2 (1.3%) 4 (3.0%) 4 (2.7%) 4 (3.0%)
Included in per-protocol analysis
(met both treatment and assessment criteria)
146 (98.6%) 135 (97.1%) 144 (97.3%) 135 (97.1%)
aRegimen A: IM Gentamicin and IM Penicillin × 7 days; Regimen B: IM Gentamicin and oral amoxicillin × 7 days; Regimen C: IM Gentamicin × 7 days and IM
Penicillin × 2 days then oral amoxicillin × 5 days; Regimen D: IM Gentamicin × 2 days and oral amoxicillin × 7 days
bInfant failed to meet both per-protocol treatment adherence and outcome assessment criteria
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6.7%. Treatment regimen D, which had only two injec-
tions of gentamicin, had the smallest proportion of treat-
ment failure. The risk difference in treatment among the
three simplified regimens and the reference treatment
varied from − 2.0% to − 4.9%. The upper limits of the
confidence intervals for all risk differences were less
than the pre-specified limit that defined similarity (5%)
with the exception of regimen B in which the upper
limit of the confidence interval was 5.2%. As expected,
the confidence intervals were greater in our smaller tudy
population compared to the larger population in the
multi-national study. However, it was encouraging to ob-
serve that, although the risk of treatment failure for all
groups was greater than in the larger study population,
all risk differences compared to the referent arm were
negative.
Most treatment failures occurred on day 4, and the most
common reason for treatment failure was the persistence
of the danger signs on day 4. Collectively, these findings
are similar to those observed in the multi-national study.
In view of these collective similarities with the multi-
national, it can reasonably be inferred that treatment regi-
mens for young infants with signs of serious bacterial
infection tested in the multi-national study would be
equally effective in the DRC.
In response to the publication of the parent study, and
a companion study investigating the effectiveness of a
simplified antibiotic treatment regimen for fast breathing
[16, 17], several respondents expressed concerns about
the context, observations and inferences drawn from
these studies [18–20]. These concerns included the un-
expectedly low mortality rates in all arms of the study,
the use of criteria for PSBI that have high sensitivity but
low specificity, the inherent over-treatment of infants
with viral rather than bacterial infection, and the
potential for emergence of resistance to these antibiotics
resulting from the widespread adoption of the simplified
regimens. These concerns were addressed in a response
by investigators from the parent study [21]. We can only
add that the parent study was a pragmatic trial to deter-
mine if a simplified alternative to the recommended
treatment for PBSI, that is not available to most infants
in low resource environments, would be equally effect-
ive. Despite the limitations imposed by the study design,
the WHO concluded that the evidence was sufficiently
compelling to recommend the simplified regimens in
low resource settings when the standard treatment is
not available [8]. Our site-specific analyses suggest that
these recommendations should be adopted in the DRC,
and perhaps other similarly impoverished and very low
resource environments.
Strengths and limitations
This is the first study in the DRC that compared simpli-
fied treatment regimens utilizing oral antibiotic regimens
in an outpatient setting for the management of neonatal
SBIs. This study was conducted within the context of
the existing health structure. However, the protocol was
highly supervised; eligibility was confirmed by specially
trained study nurses and assessment visits were conducted
by the most qualified nurses among them who were not
part of the clinical care team. This level of oversight was
necessary to ensure the quality of the research but would
not typically be available during standard clinical care.
Therefore, although the study methodology could be used
as a model for capacity-building of the existing health sys-
tem, scale up might require additional resources. Absent
these resources, it is possible that outcomes of simplified
treatments might not have compared as favorably to
standard treatment. With the support of the WHO, we
Table 4 Primary and secondary outcomes in enrolled infants–per-protocol analysis
Regimena A B C D
Number of infants analyzed 146 135 144 135
Treatment failure n (%) 17 (11.6%) 13 (9.6%) 13 (9.0%) 9 (6.7%)
Risk difference % (95% CI) referent -2.0 (− 9.2 to 5.2) -2.6 (−9.6 to 4.4) -5.0 (−11.7 to 1.7)
Reason for treatment failure
Death 1 (0.7%) 2 (1.5%) 6 (4.2%) 2 (1.5%)
Appearance of a sign of critical illness 2 (1.4%) 2 (1.5%) 2 (1.4%) 3 (2.2%)
Appearance of a new sign of serious infection 1 (0.7%) 2 (1.5%) 2 (1.4%) 0
SAE other than death 0 0 0 0
Hospitalization 0 0 0 0
No improvement in clinical condition by day 4 10 (6.8%) 6 (4.4%) 1 (0.7%) 4 (3.0%)
Reappearance of inclusion sign between days 5–8 2 (1.4%) 1 (0.7%) 2 (1.4%) 0
Presence of inclusion sign on day 8 1 (0.7%) 0 0 0
aRegimen A: IM Gentamicin and IM Penicillin × 7 days; Regimen B: IM Gentamicin and oral amoxicillin × 7 days; Regimen C: IM Gentamicin × 7 days and IM
Penicillin × 2 days then oral amoxicillin × 5 days; Regimen D: IM Gentamicin × 2 days and oral amoxicillin × 7 days
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are currently investigating the feasibility of scale up of
simplified regimens in another low-resource area of the
DRC. This ongoing study will help address concerns about
feasibility. The study was conducted in one of the poorest
regions of the country. The confirmation of effectiveness
in this area suggests that the effectiveness of these simpli-
fied treatments can be generalized to more affluent areas
of the country, where scale up might be more feasible.
Although the multi-national study had sufficient statis-
tical power to demonstrate equivalence between treat-
ments, it was not powered for site-specific outcomes.
Therefore, our results should be interpreted with some
caution. In addition, the relatively low mortality rate
among all treatment groups may reflect the intense sur-
veillance of the population. This close surveillance may
have resulted in earlier identification of high-risk infants
and earlier referral for health care. Later identification
might have occurred in the absence of the study result-
ing in more severe illness at the initiation of antibiotic
treatment, and less effectiveness of simplified treatment
regimens and higher mortality.
Implications of the results
Community-based treatments are more practical be-
cause they do not require inpatient care that is not avail-
able to many children in rural areas of the DRC. The
most simplified treatment regimen may be particularly
useful because it includes primarily on oral treatment.
We speculate that the widespread use of this strategy for
treating neonates and young infants with PSBI would re-
sult in more infants treated more effectively. This, in
turn, would reduce mortality among young infants.
Conclusion
Simplified antibiotic regimens for treating infants in rural
DRC with PSBI appear to be acceptable, feasible, safe, and
effective. Since the most simplified regimen using mainly
oral antibiotic and only two injections proved as effective
as the WHO-recommended treatment, scaling up this
regimen will more likely result in more infants treated ef-
fectively and result in reduced mortality in poor areas
where hospital care is costly and inaccessible.
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